Team McCallum

R&D for Lifetime of Life

Crizotinib cancer trials.

A trial in the current issue of the New England Journal of Medicine has found extremely positive results in a phase I/II trial of Crizotinib in advanced non-small cell lung cancer (NSCLC) where a particular genetic type is involved. Other trials have reported in other types of cancer.   And the are currently 8 more trials recruiting for patients with a variety of cancers.

The particular genetic type in question is EML4-ALK, the product of which is carcinogenic. These ALK variations happen in roughly 5% of NSCLC cases. The frequency is much higher in non-smokers with NSCLC, and in younger patients. This ALK-positive type is also thought to be the driver in around 15% of neuroblastomas. 

Crizotinib, also called PF-02341066, acts by inhibiting the action of ALK.

82 patients were treated with Crizotinib in a multi-centre trial. Standard treatment would have benefitted around 10% of this number.  At 6 months, Crizotinib resulted in partial or full remission in 57% of patients and stopped progression in a further 33%. Side effects were limited to mild gastrointestinal upsets.

The trials currently recruiting are mainly various versions of NSCLC but there are others, and one is for children. The follow-up to the trial covered here is looking for 340 patients world-wide.

Details of all the trials are at, and can be found by searching for Crizotinib or PF-02341066.


November 4, 2010 - Posted by | Cancer, Critzotinimib - PF-02341066, NSCLC - non-small cell lung cancer

No comments yet.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: